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Summary
Dravet syndrome (DS) is a refractory epileptic syndrome. Vaccination is the trig-
ger of the first seizure in about 50% of cases. Fever remains a trigger of seizures
during the course of the disease. We compared ex vivo cytokine responses to a
combined aluminium-adjuvanted vaccine of children with DS to sex- and age-
matched heathy children. Using ex vivo cytokine responses of peripheral-blood
mononuclear cells and monocytes, we found that vaccine responsiveness is biased
toward a proinflammatory profile in DS with a M1 phenotype of monocytes. We
provide new insight into immune mechanisms associated with DS that might
guide research for the development of new immunotherapeutic agents in this epi-
lepsy syndrome.
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1 | INTRODUCTION
Dravet syndrome (DS) is a refractory epileptic syndrome
starting before the age of 1. The first seizure is typically a
febrile status epilepticus. Shortly thereafter other seizures
occur leading to diagnosis in an otherwise normal infant.
Later, myoclonus, atypical absences, and partial seizures
are observed. Developmental delay becomes apparent
within the second year of life. Mutations in the voltage-
gated sodium channel gene SCN1A are the cause of DS in
70%-80% of the patients. Fever is the most common trigger
of seizures during the course of the disease.1,2 Vaccination
is the trigger of the first seizure in about 50% of cases.3,4
However, precipitation of seizure onset by immunization
does not affect the course of the disease.5
A growing body of evidence implicates a link between
inflammation and epileptic disorders.6,7 Most studies ana-
lyzed the baseline levels of proinflammatory cytokines in
tissue, sera, or cerebrospinal fluid (CSF).6,8 A restricted
number of studies evaluated cytokine levels following
ex vivo stimulation of immune cells with nonspecific acti-
vators.9 Ex vivo responses to vaccine antigens reflecting
in vivo priming with vaccines avoid seizure-induced
cofounding factors. Despite evidence for vaccine-related
seizure onset in DS, nothing is known about cytokine
response to vaccines in these patients. In DS, experimental
studies have shown that the SCN1A mutation results in a
modified neuronal excitability, which is sensitive to the
increase in body temperature.10 Whether inflammation con-
tributes to seizure occurrence has not yet been investigated.
Here, we explored if vaccinated patients with DS might be
prone to an altered cytokine response to the vaccine.
2 | POPULATIONS AND METHODS
We compared ex vivo cytokine responses to a combined
aluminium-adjuvanted vaccine (diphtheria-tetanus-pertussis-
poliomyelitis-haemophilus-B hepatitis; Infanrix-hexa,
GlaxoSmithKline Biologicals, Brentford, UK) of children
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with DS (Table S1) to sex- and age-matched heathy
children (HC). Inclusion criteria were completion of vacci-
nations and availability of residual cryopreserved periph-
eral-blood mononuclear cells (PBMCs) from blood samples
collected for standard care in stable clinical conditions
(DS) at least 15 days from any fever/infection episode or
for biological investigations in healthy bone marrow donors
before the gift (HC). The study was approved by our hos-
pital’s institutional review board (Robert-Debre Hospital,
Paris, France). Informed consent was obtained from the
parents of all children. Table S2 reports the main character-
istics of DS.
Cryopreserved PBMCs from DS and HC were simulta-
neously thawed and seeded (106/mL) into Roswell Park
Memorial Institute culture medium supplemented with
pooled human sera (10%), glutamine (1%), and antibiotics.
Cell suspensions were cultured at 37°C, in 5% CO2 atmo-
sphere, overnight with the vaccine at a predetermined opti-
mal dilution (10%) or left unstimulated. Cytokines were
measured blindly in the supernatants by a multiplexed-cyto-
kine assay using the 17-Plex human kit (Bio-Rad, Labora-
tories Inc., Marne-La-coquette, France) as described
previously.11 Supernatants from the 2 culture conditions
were analyzed for each child. Sufficient amounts of
PBMCs were available to isolate monocytes in 5 DS
patients and their respective controls. PBMCs (2 9 106)
from each individual were distributed into culture medium
(1 mL) supplemented with 10% fetal calf serum, and
monocytes were allowed to adhere to plastic by incubation
of the cell suspension in flat-bottom culture walls for
2 hours at 37°C. After careful removal of nonadherent
cells, culture medium was added (1 mL) to monocytes and
cultures were processed as described earlier for PBMCs.
Data were analyzed using the Prism 5 software (Graph-
Pad, San Diego, CA, USA). Cytokine/chemokine releases
are expressed as median and range in Table 1. Vaccine-
specific cytokine/chemokine releases are expressed as
mean  standard error of the mean (SEM) in Figure 1.
Statistical analysis was performed using Mann-Whitney
test. P values are considered statistically significant when
P < .05.
3 | RESULTS
We exclude 5 cytokines/chemokines showing either con-
centrations lying outside an interpretable range (interleukin-
8 [IL-8], monocyte chemoattractant protein-1 [MCP-1],
macrophage inflammatory protein 1-beta [MIP1-b]) or sim-
ilar levels in all culture conditions (IL-7, IL-12).
As shown in Table 1, the median levels of cytokine
release in the supernatants from unstimulated PBMCs
(background) were similar in DS and HC. In vitro
stimulation with the vaccine induced in both groups a
marked increase, over background, in the secretion of Type
1 T helper (Th1) (IL-2, IFN-c), Th2 (IL-4, IL-13), and Th17
(IL-17) T cell–derived cytokines, as well as in the proinflam-
matory (IL-1b, IL-6, tumor necrosis factor alpha [TNF-a],
granulocyte-colony stimulating factor [GCSF], granulocyte-
macrophage colony-stimulating factor [GMCSF], MIP-1b)
cytokines/chemokines and the immunoregulatory IL-10
cytokine. After subtracting the background values (Figure 1),
a remarkably higher release of TNF-a, a cytokine
implicated in the pro-inflammatory pathway of monocyte
activation and lower release of IL-10, a major anti-inflam-
matory cytokine, were observed in DS as compared to
controls. Vaccine-specific release of IL-13, a cytokine
implicated in the alternative pathway of monocyte activa-
tion and of IL-2, a cytokine implicated in the activation
and homeostasis of conventional and regulatory T cells,
were also lower in DS. Overall, the cytokine balance in
response of PBMCs to the vaccine was shifted in favor of
an inflammatory profile associated with defective IL-10
and IL-13 secretion in DS.
Adjuvants and/or components of whole pathogens con-
tained in vaccines are required for vaccine immunogenic-
ity. They act through activation of innate immune cells
including monocytes. We have therefore analyzed vac-
cine-induced cytokine releases by monocytes. Results
showed higher spontaneous release of IL-1b and IL-6 by
monocytes in DS than in HC (Table 1). In vitro stimula-
tion of monocytes with the vaccine induced a significant
increase over spontaneous release of IL-1b, IL-6, and
TNF-a in DS but of IL-10 in HC (Table 1). It is worth
noting that in accordance with T-cell depletion, Th1, Th2,
and Th17 cytokine responses were not induced by the
vaccine in monocyte preparations. After subtracting spon-
taneous release, monocyte response to the vaccine in DS
was clearly directed toward a pro-inflammatory (IL-1b,
IL-6, and TNF-a) profile associated with defective coun-
terregulatory IL-10 response (Figure 1). Monocytes are
known to exist as polarized populations including M1 and
M2 subsets. Although M1 monocytes/macrophages are
powerful inflammatory cells that produce high levels of
IL-1b, IL-6, and TNF-a cytokines, M2 monocytes/macro-
phages produce low levels of these proinflammatory
responses.12 Overall, our results support that monocytes/
macrophages are shifted in favor of a M1 proinflamma-
tory phenotype in DS.
4 | DISCUSSION
Previous data supported a role for inflammation in epi-
lepsy.6,8 Despite the clinical scenario of fever-induced
and vaccine-induced seizure in DS, there are no data
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currently available on a possible alteration of the
inflammatory response to vaccination in these patients.
Our study provides the first evidence that vaccine
responsiveness is biased toward a proinflammatory
profile in DS.
There are accumulating data on the role of IL-1b, IL-6,
and high mobility group box 1 (HMGB1) in ictogenesis
and epileptogenesis.7 In humans, immunohistochemistry
studies of surgical samples of structural epilepsies are con-
sistent with a role of these inflammatory mediators.6,7
Cytokine dosages in the blood of patients with epilepsy
have been also done, but much methodological bias exists,
as reported in a recent meta-analysis9 (timing of the blood
sample, numerous epilepsy syndromes, and seizure types
and frequency). Only IL-6 appears to be increased in the
blood of patients with epilepsy, whereas IL-1b and TNF-a
do not differ from controls.9
To avoid the bias described earlier, few studies have
investigated cytokine secretion after in vitro stimulation
of PBMCs. An increased amount of IL-1b (significant in
4/6), IL-6 (significant in 2/2), IL-10 (significant in 2/2),
and IFN-a (significant in 1/1) has been found.9 PBMCs
of patients with epilepsy and controls were stimulated
with lipopolysaccharide (LPS) in 4 studies, ds-RNA of a
common viral vector in one study, and mitogen in one
study.9
In DS, we found a clear proinflammatory profile with
an increase of IL-1b, IL-6, TNF-a, and a decrease of IL-
10 after in vitro vaccine stimulation of PBMCs. This pro-
file is unique compared to previous studies that reported
also an increase of the anti-inflammatory cytokine IL-10.9
The cytokine profile found in the monocytes of DS was
comparable to the profile in PBMCs. Together, these
results support a bias toward an M1 proinflammatory
FIGURE 1 Comparison of vaccine-specific cytokine releases by immune cells from patients and from healthy children. The mean ( SEM)
concentrations (pg/mL) of vaccine-specific cytokine release (values observed in vaccine-stimulated cultures minus values observed in
unstimulated cultures) by peripheral blood mononuclear cells (PBMCs, part A) and by monocytes (part B) are shown. The only cytokines with
concentrations significantly more elevated in vaccine-stimulated than in vaccine-unstimulated cultures are illustrated. The Mann-Whitney test was
used to compare results from patients with Dravet syndrome (DS) and healthy children (HC)l P values are indicated when statistically significant
(P < .05)
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phenotype in DS at the expense of an M2 reparative and
neuroprotective phenotype. Further studies are required to
determine whether the discrepancies found in IL-10 level
(decrease in our study and increase in past studies9) rely
on the use of polyclonal activators in previous studies
(recalled antigens in ours) or represent a selective down-
regulation of IL-10 in DS. It is notable that we also
found lower vaccine-specific release by PBMCs of IL-13,
a T cell–derived cytokine that drives monocyte differentia-
tion toward an M2 phenotype. Altogether these results
support for the first time that an altered interplay between
the innate and the adaptive immune compartments occur
in an epileptic syndrome. Whether the systemic changes
we observed may reflect similar changes in brain mono-
cytes/microglia remains to be addressed. Of interest
sodium channel modulation contributes to effector roles of
activated microglia. Pharmacological blockage of micro-
glia reduced the phagocytic activity and proinflammatory
cytokine release of microglia.13 The SCN1A mutation in
DS might then be then a factor modulating the inflamma-
tory properties of the monocytes.
Despite the small sample size, our results are suffi-
ciently reliable to support a shift toward an M1 pro-inflam-
matory phenotype of monocytes in DS. Monocytes can
adopt either M1 or M2 phenotypes.14 The activated M1
phenotype is predominately induced by an acute pathologi-
cal condition such as stroke, traumatic brain injury, or
experimentally induced systemic inflammation.14 M1
monocytes are involved in the production of proinflamma-
tory cytokines, usually associated with negative conse-
quences and that have been also described to promote
ictogenesis and epileptogenesis.6 These results provide new
insight into immune mechanisms associated with an epi-
lepsy syndrome. Previous studies have already shown that
peripheral inflammation can contribute to seizure precipita-
tion or lower brain excitability.6 Our study may also guide
research for the development of new immunotherapeutic
agents in an epilepsy syndrome for which fever, viral ill-
nesses, and immunization are frequent triggers of seizures
during the whole course of the disease.
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